Note 1 - Formation and Business of the Company (Details Textual) - USD ($)			1 Months Ended	3 Months Ended			6 Months Ended		12 Months Ended	32 Months Ended	41 Months Ended	42 Months Ended
	Nov. 06, 2020	Jun. 01, 2016	Oct. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Jun. 30, 2023	Nov. 30, 2019	Nov. 30, 2019	Aug. 31, 2021
Revenue from Contract with Customer, Excluding Assessed Tax, Total				$ 1,274,000	$ 1,615,000		$ 2,764,000	$ 2,707,000
Cancer Prevention and Research Institute of Texas [Member]
Revenue from Contract with Customer, Excluding Assessed Tax, Total											$ 20,000,000
Percentage of Cash Required to Raise in Matching Funds		50.00%
Cash Required to Raise in Matching Funds		$ 10,000,000.0
Matching Funds Required to Raise, Project Term (Year)		3 years
Cash Required in Matching Funds, Amount Raised												$ 10,000,000.0
Percentage of Grant Award Proceeds Required to Pay		400.00%
3D Medicines, Inc [Member]
Proceeds from Collaborators									$ 15,000,000	$ 27,000,000
Proceeds from Milestone Achievement			$ 6,000,000			$ 6,000,000
Collaborative Agreement, Expected Milestone Payments to be Received													$ 3,000,000
3D Medicines, Inc [Member] | Mainland China,Taiwan, Hong Kong and Macau [Member]
Proceeds from Collaborators	$ 12,000,000
Leland Stanford Junior University [Member]
Maximum Milestone Payments Upon Achievement of Clinical and Regulatory Milestones				$ 1,000,000			$ 1,000,000			$ 1,000,000